Non-small cell lung cancer · line 3 · Patritumab deruxtecan monotherapy (HERTHENA-Lung01) — EGFR-mutant NSCLC post-osimertinib + platinum
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-PATRITUMAB-DXD-NSCLC-POST-EGFR |
| ID | IND-NSCLC-EGFR-POST-OSI-PATRITUMAB-DXD |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 3L+ for EGFR-mut NSCLC post-osimertinib + platinum. HERTHENA-Lung01 source stub not yet in KB — citation flagged in commit body for source-ingest follow-up. Regulatory status fluid post-HERTHENA-Lung02.
Used By
No reverse references found in the YAML corpus.